• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of heartHeartVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Heart. Dec 1998; 80(Suppl 2): S1–S29.
PMCID: PMC1766497

Joint British recommendations on prevention of coronary heart disease in clinical practice

Full Text

The Full Text of this article is available as a PDF (489K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998 Oct;19(10):1434–1503. [PubMed]
  • Shepherd J, Betteridge DJ, Durrington P, Laker M, Lewis B, Mann J, Miller JP, Reckless JP, Thompson GR. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1245–1246. [PMC free article] [PubMed]
  • Betteridge DJ, Dodson PM, Durrington PN, Hughes EA, Laker MF, Nicholls DP, Rees JA, Seymour CA, Thompson GR, Winder AF, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993 May;69(811):359–369. [PMC free article] [PubMed]
  • Sever P, Beevers G, Bulpitt C, Lever A, Ramsay L, Reid J, Swales J. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 1993 Apr 10;306(6883):983–987. [PMC free article] [PubMed]
  • Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991 Jan;83(1):356–362. [PubMed]
  • Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998 Feb;19 (Suppl A):A2–11. [PubMed]
  • Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) 1996 Oct;91(4):399–413. [PubMed]
  • Mann JI, Crooke M, Fear H, Hay DR, Jackson RT, Neutze JM, White HD. Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J. 1993 Apr 14;106(953):133–141. [PubMed]
  • MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. [PubMed]
  • Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994 Feb 5;308(6925):363–366. [PMC free article] [PubMed]
  • Sackett DL, Anderson GD, Milner R, Feinleib M, Kannel WB. Concordance for coronary risk factors among spouses. Circulation. 1975 Oct;52(4):589–595. [PubMed]
  • Garrison RJ, Castelli WP, Feinleib M, Kannel WB, Havlik RJ, Padgett SJ, McNamara PM. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am J Epidemiol. 1979 Sep;110(3):313–321. [PubMed]
  • Pyke SD, Wood DA, Kinmonth AL, Thompson SG. Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. The British Family Heart Study. Arch Fam Med. 1997 Jul-Aug;6(4):354–360. [PubMed]
  • Daly LE, Mulcahy R, Graham IM, Hickey N. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J (Clin Res Ed) 1983 Jul 30;287(6388):324–326. [PMC free article] [PubMed]
  • Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995 Oct 9;155(18):1933–1941. [PubMed]
  • Dacosta A, Guy JM, Tardy B, Gonthier R, Denis L, Lamaud M, Cerisier A, Verneyre H. Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J. 1993 Dec;14(12):1709–1711. [PubMed]
  • Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, Sherman SE, Cleveland M, Antonuccio DO, Antonnucio DO, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996 Dec 12;335(24):1792–1798. [PubMed]
  • Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–761. [PubMed]
  • de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11;343(8911):1454–1459. [PubMed]
  • Mancini GB. Angiographic trials of lipid-lowering therapy: an update. Curr Opin Lipidol. 1995 Dec;6(6):379–385. [PubMed]
  • Manson JE, Gaziano JM, Jonas MA, Hennekens CH. Antioxidants and cardiovascular disease: a review. J Am Coll Nutr. 1993 Aug;12(4):426–432. [PubMed]
  • Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I--Analysis of observational data among populations. BMJ. 1991 Apr 6;302(6780):811–815. [PMC free article] [PubMed]
  • Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III--Analysis of data from trials of salt reduction. BMJ. 1991 Apr 6;302(6780):819–824. [PMC free article] [PubMed]
  • Stamler R, Stamler J, Grimm R, Gosch FC, Elmer P, Dyer A, Berman R, Fishman J, Van Heel N, Civinelli J, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA. 1987 Mar 20;257(11):1484–1491. [PubMed]
  • Swales JD. Non-pharmacological antihypertensive therapy. Eur Heart J. 1988 May;9 (Suppl G):45–52. [PubMed]
  • Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomised controlled trial. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1468–1471. [PMC free article] [PubMed]
  • Rouse IL, Beilin LJ, Armstrong BK, Vandongen R. Blood-pressure-lowering effect of a vegetarian diet: controlled trial in normotensive subjects. Lancet. 1983 Jan 1;1(8314-5):5–10. [PubMed]
  • Smith SJ, Markandu ND, Sagnella GA, MacGregor GA. Moderate potassium chloride supplementation in essential hypertension: is it additive to moderate sodium restriction? Br Med J (Clin Res Ed) 1985 Jan 12;290(6462):110–113. [PMC free article] [PubMed]
  • Klatsky AL, Friedman GD, Siegelaub AB, Gérard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med. 1977 May 26;296(21):1194–1200. [PubMed]
  • Marmot MG, Elliott P, Shipley MJ, Dyer AR, Ueshima H, Beevers DG, Stamler R, Kesteloot H, Rose G, Stamler J. Alcohol and blood pressure: the INTERSALT study. BMJ. 1994 May 14;308(6939):1263–1267. [PMC free article] [PubMed]
  • Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA. 1988 Aug 19;260(7):945–950. [PubMed]
  • O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, Jr, Hennekens CH. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation. 1989 Aug;80(2):234–244. [PubMed]
  • Horgan J, Bethell H, Carson P, Davidson C, Julian D, Mayou RA, Nagle R. Working party report on cardiac rehabilitation. Br Heart J. 1992 May;67(5):412–418. [PMC free article] [PubMed]
  • Levens NR, Ksander GM, Zimmerman MB, Mullane KM. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors. Hypertension. 1989 Jan;13(1):51–62. [PubMed]
  • Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986 Aug 14;315(7):423–429. [PubMed]
  • Moss AJ, Oakes D, Rubison M, McDermott M, Carleen E, Eberly S, Brown M. Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol. 1991 Aug 15;68(5):429–433. [PubMed]
  • Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. [PubMed]
  • Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987 Mar 14;1(8533):581–584. [PubMed]
  • D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991 Aug 17;303(6799):385–389. [PMC free article] [PubMed]
  • Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet. 1991 Nov 23;338(8778):1281–1285. [PubMed]
  • Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990 Jun 14;322(24):1700–1707. [PubMed]
  • Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994 Feb 5;308(6925):367–372. [PMC free article] [PubMed]
  • Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994 Feb 5;308(6925):373–379. [PMC free article] [PubMed]
  • Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996 Mar 30;347(9005):849–853. [PubMed]
  • Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) Lancet. 1995 May 20;345(8960):1274–1275. [PubMed]
  • Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. [PubMed]
  • Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. [PubMed]
  • MBewu AD, Durrington PN, Bulleid S, Mackness MI. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 1993 Oct;103(1):65–71. [PubMed]
  • Shaukat N, Ashraf SS, Mackness MI, Mbewu AD, Bhatnagar D, Durrington PN. A prospective study of serum lipoproteins after coronary artery bypass surgery. QJM. 1994 Sep;87(9):539–545. [PubMed]
  • Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis. 1997 May;131(1):1–5. [PubMed]
  • Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995 Apr 15;91(8):2274–2282. [PubMed]
  • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. [PubMed]
  • Feher MD, Foxton J, Banks D, Lant AF, Wray R. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease. Br Heart J. 1995 Jul;74(1):14–17. [PMC free article] [PubMed]
  • Farrer M, Fulcher G, Albers CJ, Neil HA, Adams PC, Alberti KG. Patients undergoing coronary artery bypass graft surgery are at high risk of impaired glucose tolerance and diabetes mellitus during the first postoperative year. Metabolism. 1995 Aug;44(8):1016–1027. [PubMed]
  • Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997 Apr;20(4):614–620. [PubMed]
  • Dean JD, Durrington PN. Treatment of dyslipoproteinaemia in diabetes mellitus. Diabet Med. 1996 Apr;13(4):297–312. [PubMed]
  • Durrington P. Statins and fibrates in the management of diabetic dyslipidemia. Diabet Med. 1997 Jul;14(7):513–516. [PubMed]
  • Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995 Jul;26(1):57–65. [PubMed]
  • Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):303–310. [PubMed]
  • Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992 Mar 15;19(4):842–850. [PubMed]
  • Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990 Jul 19;323(3):147–152. [PubMed]
  • Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed]
  • Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970 Mar 7;1(7645):485–489. [PubMed]
  • Gersh BJ, Rihal CS, Rooke TW, Ballard DJ. Evaluation and management of patients with both peripheral vascular and coronary artery disease. J Am Coll Cardiol. 1991 Jul;18(1):203–214. [PubMed]
  • Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983 Feb 17;308(7):377–381. [PubMed]
  • Wenting GJ, Derkx FH, Tan-Tjiong LH, van Seyen AJ, Man in't Veld AJ, Schalekamp MA. Risks of angiotensin converting enzyme inhibition in renal artery stenosis. Kidney Int Suppl. 1987 May;20:S180–S183. [PubMed]
  • Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993 May 22;306(6889):1367–1373. [PMC free article] [PubMed]
  • Austoker J, Sanders D, Fowler G. Smoking and cancer: smoking cessation. BMJ. 1994 Jun 4;308(6942):1478–1482. [PMC free article] [PubMed]
  • Dobson AJ, Alexander HM, Heller RF, Lloyd DM. How soon after quitting smoking does risk of heart attack decline? J Clin Epidemiol. 1991;44(11):1247–1253. [PubMed]
  • Rosenberg SA. Combined modality therapy of cancer. What is it and when does it work? N Engl J Med. 1985 Jun 6;312(23):1512–1514. [PubMed]
  • Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990 Jan 25;322(4):213–217. [PubMed]
  • Watkins LO, Neaton JD, Kuller LH. Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1986 Mar 1;57(8):538–545. [PubMed]
  • Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994 Jan 24;154(2):169–175. [PubMed]
  • Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA. 1989 Nov 3;262(17):2395–2401. [PubMed]
  • Paffenbarger RS, Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993 Feb 25;328(8):538–545. [PubMed]
  • Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990 Oct;132(4):612–628. [PubMed]
  • Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med. 1994 Jun 2;330(22):1549–1554. [PubMed]
  • Morris JN, Clayton DG, Everitt MG, Semmence AM, Burgess EH. Exercise in leisure time: coronary attack and death rates. Br Heart J. 1990 Jun;63(6):325–334. [PMC free article] [PubMed]
  • Neil HA, Roe L, Godlee RJ, Moore JW, Clark GM, Brown J, Thorogood M, Stratton IM, Lancaster T, Mant D, et al. Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ. 1995 Mar 4;310(6979):569–573. [PMC free article] [PubMed]
  • Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991 Oct 19;303(6808):953–957. [PMC free article] [PubMed]
  • Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994 Apr;50(2):272–298. [PubMed]
  • Linjer E, Hansson L. Underestimation of the true benefits of antihypertensive treatment: an assessment of some important sources of error. J Hypertens. 1997 Mar;15(3):221–225. [PubMed]
  • Zanchetti A. Goals of antihypertensive treatment: prevention of cardiovascular events and prevention of organ damage. Blood Press. 1992 Dec;1(4):205–211. [PubMed]
  • MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. [PubMed]
  • Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980 Jun;61(6):1179–1182. [PubMed]
  • Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997 Sep 13;350(9080):757–764. [PubMed]
  • Jackson R, Barham P, Bills J, Birch T, McLennan L, MacMahon S, Maling T. Management of raised blood pressure in New Zealand: a discussion document. BMJ. 1993 Jul 10;307(6896):107–110. [PMC free article] [PubMed]
  • Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension. 1989 May;13(5 Suppl):I2–12. [PubMed]
  • Myers MG, Carruthers SG, Leenen FH, Haynes RB. Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ. 1989 May 15;140(10):1141–1146. [PMC free article] [PubMed]
  • Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985 Jun 15;1(8442):1349–1354. [PubMed]
  • Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993 Apr 1;328(13):914–921. [PubMed]
  • Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990 Apr 14;300(6730):975–978. [PMC free article] [PubMed]
  • Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984 Oct-Dec;3(4):409–422. [PubMed]
  • Gross V, Luft FC. Nisoldipine and pressure-natriuresis curves in transgenic (mRen2)27 rats. J Hypertens. 1996 Apr;14(4):529–535. [PubMed]
  • Treating mild hypertension. Report of the British Hypertension Society working party. BMJ. 1989 Mar 18;298(6675):694–698. [PMC free article] [PubMed]
  • Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755–1762. [PubMed]
  • Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998 Jun;16(6):747–752. [PubMed]
  • Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990 Dec;82(6):1916–1924. [PubMed]
  • Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992 Feb 15;304(6824):431–434. [PMC free article] [PubMed]
  • Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet. 1992 Dec 5;340(8832):1405–1406. [PubMed]
  • Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM., Jr Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615–1622. [PubMed]
  • Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A. 1973 Oct;70(10):2804–2808. [PMC free article] [PubMed]
  • Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990 Dec 19;264(23):3007–3012. [PubMed]
  • Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987 Apr;3(2):463–524. [PubMed]
  • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229–234. [PubMed]
  • Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980 Jun 28;1(8183):1373–1376. [PubMed]
  • Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990 Jun 6;263(21):2893–2898. [PubMed]
  • Barrett-Connor E, Wingard DL, Criqui MH, Suarez L. Is borderline fasting hyperglycemia a risk factor for cardiovascular death? J Chronic Dis. 1984;37(9-10):773–779. [PubMed]
  • Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539–553. [PubMed]
  • Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996 Dec 18;276(23):1886–1892. [PubMed]
  • Johnston CI, Cooper ME, Nicholls GM. Meeting report of the International Society of Hypertension Conference on Hypertension and Diabetes. J Hypertens. 1992 Apr;10(4):393–397. [PubMed]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. [PubMed]
  • Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet. 1995 Oct 21;346(8982):1080–1084. [PubMed]
  • Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med. 1996 Nov 28;335(22):1682–1683. [PubMed]
  • Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998 Jul 18;352(9123):213–219. [PubMed]
  • Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997 Feb;29(2):641–650. [PubMed]
  • Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997 Mar 15;314(7083):783–788. [PMC free article] [PubMed]
  • Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis. 1986 Nov-Dec;29(3 Suppl 1):29–54. [PubMed]
  • Durrington PN. Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta. 1980 May 21;104(1):11–23. [PubMed]
  • Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992 Jul;15(7):820–825. [PubMed]
  • Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, Jacobs C. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron. 1982;31(2):103–110. [PubMed]
  • Short CD, Durrington PN. Hyperlipidaemia and renal disease. Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):777–806. [PubMed]
  • Bulpitt CJ, Beevers DG, Butler A, Coles EC, Hunt D, Munro-Faure AD, Newson RB, O'Riordan PW, Petrie JC, Rajagopalan B, et al. The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens. 1986 Feb;4(1):93–99. [PubMed]
  • Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939–945. [PubMed]
  • Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997 Sep 1;127(5):337–345. [PubMed]
  • Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877–884. [PubMed]
  • Anastos K, Charney P, Charon RA, Cohen E, Jones CY, Marte C, Swiderski DM, Wheat ME, Williams S. Hypertension in women: what is really known? The Women's Caucus, Working Group on Women's Health of the Society of General Internal Medicine. Ann Intern Med. 1991 Aug 15;115(4):287–293. [PubMed]
  • Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med. 1997 May 15;126(10):761–767. [PubMed]
  • Crane MG, Harris JJ, Winsor W., 3rd Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med. 1971 Jan;74(1):13–21. [PubMed]
  • Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ. 1997 Jul 19;315(7101):149–153. [PMC free article] [PubMed]
  • Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993 Apr 15;328(15):1069–1075. [PubMed]
  • McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol. 1989;42(7):597–609. [PubMed]
  • Bhatnagar D, Anand IS, Durrington PN, Patel DJ, Wander GS, Mackness MI, Creed F, Tomenson B, Chandrashekhar Y, Winterbotham M, et al. Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet. 1995 Feb 18;345(8947):405–409. [PubMed]
  • McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S, Riemersma RA. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in east London. Br Heart J. 1988 Nov;60(5):390–396. [PMC free article] [PubMed]
  • Cruickshank JK, Cooper J, Burnett M, MacDuff J, Drubra U. Ethnic differences in fasting plasma C-peptide and insulin in relation to glucose tolerance and blood pressure. Lancet. 1991 Oct 5;338(8771):842–847. [PubMed]
  • McKeigue PM, Pierpoint T, Ferrie JE, Marmot MG. Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia. 1992 Aug;35(8):785–791. [PubMed]
  • Shelgikar KM, Hockaday TD, Yajnik CS. Central rather than generalized obesity is related to hyperglycaemia in Asian Indian subjects. Diabet Med. 1991 Oct;8(8):712–717. [PubMed]
  • Laws A, Jeppesen JL, Maheux PC, Schaaf P, Chen YD, Reaven GM. Resistance to insulin-stimulated glucose uptake and dyslipidemia in Asian Indians. Arterioscler Thromb. 1994 Jun;14(6):917–922. [PubMed]
  • Sevak L, McKeigue PM, Marmot MG. Relationship of hyperinsulinemia to dietary intake in south Asian and European men. Am J Clin Nutr. 1994 May;59(5):1069–1074. [PubMed]
  • Casper M, Wing S, Strogatz D. Variation in the magnitude of black-white differences in stroke mortality by community occupational structure. J Epidemiol Community Health. 1991 Dec;45(4):302–306. [PMC free article] [PubMed]
  • Klatsky AL, Armstrong MA, Friedman GD. Racial differences in cerebrovascular disease hospitalizations. Stroke. 1991 Mar;22(3):299–304. [PubMed]
  • Petrie JC, O'Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed) 1986 Sep 6;293(6547):611–615. [PMC free article] [PubMed]
  • Pickering TG. Can ambulatory blood pressure monitoring improve the diagnosis of mild hypertension? J Hypertens Suppl. 1990 Dec;8(6):S43–S47. [PubMed]

Figures and Tables

Figure 1  Figure 1
Joint British Societies coronary risk prediction charts for men and women. The chart should not be used for predicting risk in patients with coronary or other major atherosclerotic disease, familial hypercholesterolaemia or those with renal dysfunction. ...
Figure 2
Absolute CHD risk and management of blood pressure in primary prevention of CHD and other atherosclerotic disease. CHD risk, non-fatal myocardial infarction and coronary death over 10 years.
Figure 3
Absolute CHD risk and management of blood lipids in primary prevention of CHD and other atherosclerotic disease. CHD risk, non-fatal myocardial infarction and coronary death over 10 years.

Articles from Heart are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...